Lyndra Inc., a Watertown, MA-based biopharmaceutical company, formed a joint venture with Global Drug Commercialization Center (GDCC) to commercialize its medicines in China.
With the creation of this joint venture, GDCC will invest $80m for development of products tailored to the Chinese market.
Led by Co-founder and CEO Amy Schulman, Lyndra is developing ultra-long-acting oral therapies through a platform based on technology developed in the laboratory of Dr. Robert Langer at the Massachusetts Institute of Technology with funding from the Bill and Melinda Gates Foundation.
Led by Ms. Karimah Es Sabar, CEO, GDCC is the drug development and marketing affiliate in China of Quark Ventures and the Global Health Sciences Fund, which made its first Series A investment in Lyndra just over a year ago.
FinSMEs
02/05/2018